A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE009 (AUS) · Dr. Novak
consented 2022-12-18
AEs
3
Serious
0
Dropout signal
–
Adverse events
mild
assessed
Grade 1 Stomatitis — outcome: UNKNOWN; onset 2023-03-19 (study day 73); relationship: not assessed
moderate
assessed
Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2023-09-02 (study day 240); relationship: not assessed
moderate
assessed
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-02-17 (study day 408); relationship: Y
Data queries
No data queries.